Doctor of Philosophy

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

Retrieved on: 
Tuesday, April 30, 2024
University of Southern California, Efficacy, University, UCSD, Radiation, Resection, Regenerative medicine, HGG, TMZ, Doctor of Philosophy, RRV, GBM, WGS, Glioblastoma, Artificial intelligence, Depression, CIRM, UCSF, USC, Intravenous therapy, Neoplasm, Clinical trial, Medicine, SHROOM3, Whole genome sequencing, SAN, Medical imaging

We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.

Key Points: 
  • We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.
  • DB107 consists of two components: DB107–RRV (vocimagene amiretrorepvec) as a prodrug activator gene therapy and DB107–FC (extended-release 5–fluorocytosine [5–FC]) as an oral prodrug.
  • Retrospective analysis of an earlier randomized clinical trial in patients with recurrent HGG suggested improved overall survival in DGM7–positive patients treated with DB107.
  • "We are excited to conduct this novel trial which will be investigating several new approaches for the first time in patients with newly–diagnosed high–grade glioma.

School Specialty Announces Winners of the 2024 Crystal Apple Awards Celebrating Inspirational Teachers

Retrieved on: 
Tuesday, April 30, 2024
System, Teaching, Edison Elementary School, Commonwealth, Doctor of Philosophy, Parent, Commonwealth Charter Academy, Friends, Family, Student, Nursing

GREENVILLE, Wis., April 30, 2024 /PRNewswire-PRWeb/ -- School Specialty, a leading provider of learning environments and supplies to the pre-K–12 education market, today announced the 2024 winners of its annual Crystal Apple Awards, which celebrate teachers who embody inspiration, leadership, and passion in teaching.

Key Points: 
  • "Having witnessed firsthand the immense efforts and lifelong impact educators have on students, I am profoundly honored to be part of the Crystal Apple Awards," said Sue Ann Highland, PhD, the national education strategist at School Specialty.
  • School Specialty selects 10 finalists from the nominees, and three winners are then selected by public vote.
  • This year's winners will each receive a personalized trophy and a $500 gift certificate from School Speciality for themselves, as well as a $250 School Specialty gift certificate for their school.
  • Finalists for the Crystal Apple Awards receive a $100 School Specialty merchandise certificate for themselves and an additional $100 certificate for their school.

AANA President Appointed to VA's National Research Advisory Council

Retrieved on: 
Tuesday, April 30, 2024
Congress, DNP, FAAN, Systematic review, Veterans' affairs, Doctor of Philosophy, Research, Anesthesia, Military reserve force, Veteran, Cochrane US Network, Certified Registered Nurse Anesthetist, Multimedia, Translation, Health, Nursing

ROSEMONT, Ill., April 30, 2024 /PRNewswire/ -- (AANA) —Dru Riddle, PhD, DNP, CRNA, FAAN, president of the American Association of Nurse Anesthesiology (AANA), has been appointed to the Department of Veterans Affairs' (VA) National Research Advisory Council by the Secretary of the VA, Denis McDonough.

Key Points: 
  • ROSEMONT, Ill., April 30, 2024 /PRNewswire/ -- (AANA) —Dru Riddle, PhD, DNP, CRNA, FAAN, president of the American Association of Nurse Anesthesiology (AANA), has been appointed to the Department of Veterans Affairs' (VA) National Research Advisory Council by the Secretary of the VA, Denis McDonough.
  • "I'm honored to be chosen to serve on the council and assist the VA with a national research program that is focused on providing quality healthcare to our veterans," said Riddle.
  • The National Research Advisory Council advises the VA secretary on all matters related to its research and development program.
  • Riddle's term on the VA National Research Advisory Council concludes on March 31, 2026.

Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations

Retrieved on: 
Tuesday, April 30, 2024
FDA, Inflammation, CMO, VEGF-A, Clinical trial, Food, Diabetic retinopathy, Doctor of Philosophy, IND, Therapy, Ranibizumab, Senior, Patient, Master of Science, Pediatrics, Summit Meeting, Season, DME, IL-6, JZ, SAN

EB-105 is a novel trispecific fusion antibody targeting VEGF-A (and isomers), VEGF-B, placental growth factor (PlGF), angiopoetin-2 (Ang-2), and interleukin-6 receptor (IL-6R) for the treatment of DME.

Key Points: 
  • EB-105 is a novel trispecific fusion antibody targeting VEGF-A (and isomers), VEGF-B, placental growth factor (PlGF), angiopoetin-2 (Ang-2), and interleukin-6 receptor (IL-6R) for the treatment of DME.
  • "Elevated levels of IL-6 in the vitreous have been well-documented in patients with DME, even with on-going anti-VEGF treatments.
  • Furthermore, IL-6 is over-expressed and contributes to inflammation and vascular permeability in other retinal disorders including neovascular (wet) age-related macular degeneration, retinal vein occlusion, and uveitic macular edema.
  • Details of EB-105 mechanism of action and preclinical science will be presented at the following venues:
    Oral presentation.

Setting the New Standard: Macorva's Performance Management Workflow Delivers a Responsible AI Solution for HR Leaders

Retrieved on: 
Tuesday, April 30, 2024
Automation, OKR, Head, Bias, Responsibility, AI, HR, Engagement, Research, Motivation, Doctor of Philosophy, Growth, SMART, Workflow, LMS, Organization, Medical device

HOUSTON, April 30, 2024 /PRNewswire/ -- Macorva, a leading provider of employee experience and performance management solutions, today announced the launch of its advanced AI-generated performance review workflow tool. Designed to meet the critical needs of HR leaders and managers, this innovative solution streamlines the performance review process, ensuring time savings, improved efficiency, fairness, and consistency across the organization.

Key Points: 
  • As 76% of HR leaders plan to adopt AI solutions in the next 12-24 months, Macorva's AI Performance Management Workflow offers a responsible approach, streamlining the creation of employee documents and enhancing risk analysis.
  • HOUSTON, April 30, 2024 /PRNewswire/ -- Macorva , a leading provider of employee experience and performance management solutions, today announced the launch of its advanced AI-generated performance review workflow tool .
  • Research shows that Macorva's AI tool can save each manager an average of 2 hours during the performance review process.
  • Recognizing the concerns HR leaders have regarding the potential misuse of generative AI, Macorva's workflow is specifically designed to mitigate these risks and ensure responsible AI implementation.

Caris Life Sciences and COTA, Inc. Announce Collaboration to Expand Collective Multi-Modal Data Offering

Retrieved on: 
Tuesday, April 30, 2024
Sequence, Cancer, AUC, WTS, AI, Prognosis, RNA, MD, Partnership, Doctor of Philosophy, Research, DNA, Health information management, Data, Patient, Record, RWD, Health, WES, Biomarker, Medicine, Quality of life, COTA, Medical imaging

IRVING, Texas and NEW YORK, April 30, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, and COTA, Inc. (COTA), an oncology real-world data (RWD) and analytics company used by the world's leading pharmaceutical companies, today announced a collaboration to expand their multi-modal data offerings to support and accelerate biopharmaceutical drug development and patient care. 

Key Points: 
  • The combination of the breadth and depth of Caris' genomic, transcriptomic, proteomic and imaging data and COTA's high-quality curated clinical data that captures the treatment journeys and outcomes of cancer patients will result in a broad real-world, multi-modal data offering, at scale, to power the next wave of cancer therapeutics.
  • "Caris' partnership with COTA will enable biopharma to leverage a more complete dataset to power research and AI approaches for therapeutic development.
  • Caris was the first in the molecular diagnostic industry to provide Whole Exome Sequencing (WES) DNA coverage and Whole Transcriptome Sequencing (WTS) RNA coverage for every viable sample.
  • "By combining COTA's high-quality, curated data sourced from electronic health records with Caris' molecular data, life sciences researchers will be able to capture previously unseen insights to optimize cancer treatments that can improve a patient's prognosis and quality of life," said C.K.

Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)

Retrieved on: 
Tuesday, April 30, 2024
Doctor of Philosophy, University, Cancer, HKEX, Eli Lilly, Partnership, Columbia University, Molecular biology, Novartis, Science, Bristol Myers Squibb, Patient, Acquisition, Peking University, CBO, SAN, Ophthalmology, AstraZeneca, Pharmaceutical industry

In this role, Dr. Zhang will be responsible for Innovent's global strategy and business development, and his reporting line is Dr. Michael Yu, founder, Chairman and CEO of Innovent.

Key Points: 
  • In this role, Dr. Zhang will be responsible for Innovent's global strategy and business development, and his reporting line is Dr. Michael Yu, founder, Chairman and CEO of Innovent.
  • Dr. Zhang brings over 20 years of industry experience across the entire drug research, development and commercialization spectrum.
  • Prior to joining Innovent, Dr. Zhang served as CBO at Gracell Biotechnologies and NeoImmuneTech.
  • Most recently, Dr. Zhang led Gracell's global partnership discussions, which resulted in a $1.2B acquisition by AstraZeneca.

UT Health San Antonio-led STRONG STAR Consortium secures $17 million in DOD research funding for brain injuries, PTSD and more

Retrieved on: 
Tuesday, April 30, 2024
Neuroimaging, University, Psychiatry, Post-traumatic stress disorder, Tinnitus, DOD, Trauma, Risk, Veterans' affairs, PTSD, Sleep, CQD, University of Texas System, Doctor of Philosophy, Research, Suicidal ideation, Military personnel, Concussion, Headache, Veteran, Cognitive processing therapy, Patient, STRONG, Workforce, Brain, Traumatic brain injury, Clinical trial, Function (mathematics), Ketamine, Chronic pain, SAN, Defense, Nursing

SAN ANTONIO, April 29, 2024 /PRNewswire-PRWeb/ -- In a recent round of grant awards, the STRONG STAR Consortium based at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was selected by the U.S. Department of Defense for a total of $17 million in funding to launch eight new research projects focused on traumatic brain injury and psychological health.

Key Points: 
  • "Another is tinnitus, which is a persistent ringing in the ears that can develop after a brain injury.
  • Tinnitus is also commonly comorbid with PTSD, and it both contributes to and is impacted by psychological distress."
  • Some of these projects will be led by UT Health San Antonio investigators and others by STRONG STAR collaborators at other institutions, with research participants from a variety of military and VA study sites.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of $413 million.

ARUP Statement on FDA Final Rule to Regulate Laboratory-Developed Tests as Medical Devices

Retrieved on: 
Monday, April 29, 2024
FDA, Congress, Laboratory, ARUP, CLEP, MDA, MD, Doctor of Philosophy, Synovial joint, ARUP Laboratories, Patient, Medicare, Health, Medical device

SALT LAKE CITY, April 29, 2024 /PRNewswire/ -- A final FDA rule regulating laboratory-developed tests (LDTs) as medical devices does not address serious concerns raised by ARUP Laboratories and the clinical laboratory community, and the company's stance on the rule has not changed, CEO Andy Theurer said today.

Key Points: 
  • SALT LAKE CITY, April 29, 2024 /PRNewswire/ -- A final FDA rule regulating laboratory-developed tests (LDTs) as medical devices does not address serious concerns raised by ARUP Laboratories and the clinical laboratory community, and the company's stance on the rule has not changed, CEO Andy Theurer said today.
  • "ARUP is evaluating and reviewing the final rule, including any changes, internally and with our industry partners, to determine next steps," Theurer said.
  • Congress gave the FDA authority to regulate medical devices, but if Congress had intended the FDA to regulate laboratory-developed testing services as medical devices, lawmakers would have included this concept in the text of the Medical Device Amendments of 1976 (MDA), and it did not.
  • He added that he and ARUP Chief Compliance Officer Jonathan Carr will host an educational webinar on the FDA rule.

AANA Presents U.S. Representative Jen Kiggans With National Health Leadership Award

Retrieved on: 
Monday, April 29, 2024
Education, Congress, Congressional district, Assembly, DNP, Veterans' affairs, Health, Gallup, American Medical Association, Doctor of Philosophy, House, Human, ICAN, Federation, Patient, Legislation, Society, Access, American Society of Anesthesiologists, Medicare, Committee, Certified Registered Nurse Anesthetist, Multimedia, ASA, Licensure, Nursing

ROSEMONT, Ill., April 29, 2024 /PRNewswire/ -- (AANA) – The American Association of Nurse Anesthesiology (AANA) recognized U.S. Representative Jen Kiggans (R-VA) as the winner of its National Health Leadership Award for 2024 at its Mid-Year Assembly, April 20-24, in Washington, DC.

Key Points: 
  • ROSEMONT, Ill., April 29, 2024 /PRNewswire/ -- (AANA) – The American Association of Nurse Anesthesiology (AANA) recognized U.S. Representative Jen Kiggans (R-VA) as the winner of its National Health Leadership Award for 2024 at its Mid-Year Assembly, April 20-24, in Washington, DC.
  • The National Health Leadership Award was established in 1992 and is presented to individuals working at the federal government level who have made a significant contribution to the formation of national health policy.
  • Kiggans is a freshman representative, serving Virginia's 2nd Congressional District.
  • I am honored to receive the AANA National Health Leadership Award and will continue to work across the aisle to pass legislation to improve nursing recruitment, education, and retention."